Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Comorbidities
Chronic Effects of Adaptive Servo-Ventilation Therapy on Mortality and the Urgent Rehospitalization Rate in Patients Experiencing Recurrent Admissions for Heart Failure ― A Multicenter Prospective Observational Study (SAVIOR-L) ―
Yoshihiro FukumotoTakeshi TadaHideaki SuzukiYuji NishimotoKenji MoriuchiTakuo ArikawaHitoshi AdachiShin-ichi MomomuraYoshihiko SeinoYoshio YasumuraHiroyuki YokoyamaGo HiasaTakayuki HidakaShoichiro NoharaHideki OkayamaHiroyuki TsutsuiTakatoshi KasaiYoshifumi TakataMika EnomotoYusuke SaigusaKouji YamamotoKoichiro KinugawaYasuki Kihara on behalf of the SAVIOR-L Investigators
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML
Supplementary material

2024 Volume 88 Issue 5 Pages 692-702

Details
Abstract

Background: This study investigated whether the chronic use of adaptive servo-ventilation (ASV) reduces all-cause mortality and the rate of urgent rehospitalization in patients with heart failure (HF).

Methods and Results: This multicenter prospective observational study enrolled patients hospitalized for HF in Japan between 2019 and 2020 who were treated either with or without ASV therapy. Of 845 patients, 110 (13%) received chronic ASV at hospital discharge. The primary outcome was a composite of all-cause death and urgent rehospitalization for HF, and was observed in 272 patients over a 1-year follow-up. Following 1:3 sequential propensity score matching, 384 patients were included in the subsequent analysis. The median time to the primary outcome was significantly shorter in the ASV than in non-ASV group (19.7 vs. 34.4 weeks; P=0.013). In contrast, there was no significant difference in the all-cause mortality event-free rate between the 2 groups.

Conclusions: Chronic use of ASV did not impact all-cause mortality in patients experiencing recurrent admissions for HF.

Content from these authors
© 2024, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
feedback
Top